WARFASA 2012

NCT00222677

1 Treatments

Studied treatment  
aspirin, 100 mg daily for 2 years

Control treatment  
placebo

Concomittant treatments  
-

2 Patients

Patients  
patients with first-ever unprovoked venous thromboembolism who had completed 6 to 18 months of oral anticoagulant treatment

Inclusion criteria  
-

Exclusion criteria  
-

3 Methods

Blinding  
double-blind

Design  
Parallel groups

Centers  
multicenter

Geographical area  
-

Sizes  
205/197

4 Results

<table>
<thead>
<tr>
<th>Endpoint</th>
<th>T1</th>
<th>T0</th>
<th>d</th>
<th>95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>fatal PE</td>
<td>1/205</td>
<td>1/197</td>
<td>0,96</td>
<td>[0,06; 15,47]</td>
</tr>
<tr>
<td>DVT only</td>
<td>16/205</td>
<td>28/197</td>
<td>0,55</td>
<td>[0,29; 1,05]</td>
</tr>
<tr>
<td>PE</td>
<td>11/205</td>
<td>14/197</td>
<td>0,76</td>
<td>[0,33; 1,71]</td>
</tr>
<tr>
<td>major vascular events</td>
<td>8/205</td>
<td>5/197</td>
<td>1,54</td>
<td>[0,49; 4,78]</td>
</tr>
<tr>
<td>recurrence of venous thromboembolism</td>
<td>28/205</td>
<td>43/197</td>
<td>0,63</td>
<td>[0,37; 1,06]</td>
</tr>
<tr>
<td>death</td>
<td>6/205</td>
<td>5/197</td>
<td>1,15</td>
<td>[0,35; 3,84]</td>
</tr>
<tr>
<td>net clinical benefit</td>
<td>-/205</td>
<td>-/197</td>
<td>NA</td>
<td>-</td>
</tr>
<tr>
<td>major and Clinically relevant nonmajor bleeding</td>
<td>4/205</td>
<td>4/197</td>
<td>0,96</td>
<td>[0,24; 3,90]</td>
</tr>
<tr>
<td>major bleeding</td>
<td>1/205</td>
<td>1/197</td>
<td>0,96</td>
<td>[0,06; 15,47]</td>
</tr>
</tbody>
</table>
5 References